{"id":"https://openalex.org/W2096249138","doi":"https://doi.org/10.3317/jraas.2000.056","title":"Will more complete inhibition of the RAAS with angiotensin receptor blockade improve survival following myocardial infarction?","display_name":"Will more complete inhibition of the RAAS with angiotensin receptor blockade improve survival following myocardial infarction?","publication_year":2000,"publication_date":"2000-06-01","ids":{"openalex":"https://openalex.org/W2096249138","doi":"https://doi.org/10.3317/jraas.2000.056","mag":"2096249138","pmid":"https://pubmed.ncbi.nlm.nih.gov/17199221"},"language":"en","primary_location":{"id":"doi:10.3317/jraas.2000.056","doi":"https://doi.org/10.3317/jraas.2000.056","is_oa":false,"landing_page_url":"https://doi.org/10.3317/jraas.2000.056","pdf_url":null,"source":{"id":"https://openalex.org/S107472416","display_name":"Journal of the Renin-Angiotensin-Aldosterone System","issn_l":"1470-3203","issn":["1470-3203","1752-8976"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","norway-1","poland-40","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the Renin-Angiotensin-Aldosterone System","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5031560506","display_name":"Marc Alan Pfeffer","orcid":"https://orcid.org/0000-0003-3876-7568","observed_orcids":["https://orcid.org/0000-0003-3876-7568"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Marc A Pfeffer","raw_affiliation_strings":["Harvard Medical School, Cardiovascular Division, Brigham and Women's Hospital, Boston, USA","Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA#TAB#"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Harvard Medical School, Cardiovascular Division, Brigham and Women's Hospital, Boston, USA","institution_ids":["https://openalex.org/I1283280774","https://openalex.org/I136199984"]},{"raw_affiliation_string":"Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA#TAB#","institution_ids":["https://openalex.org/I1283280774","https://openalex.org/I136199984"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5031560506"],"corresponding_institution_ids":["https://openalex.org/I1283280774","https://openalex.org/I136199984"],"apc_list":{"value":4150,"currency":"USD","value_usd":4150},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.20383849,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"1","issue":"2_suppl","first_page":"41","last_page":"44"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11001","display_name":"Renin-Angiotensin System Studies","score":0.9794999957084656,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11001","display_name":"Renin-Angiotensin System Studies","score":0.9794999957084656,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10292","display_name":"Acute Myocardial Infarction Research","score":0.01360000018030405,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10198","display_name":"Heart Failure Treatment and Management","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/angiotensin-receptor-blockers","display_name":"angiotensin receptor blockers","score":0.9049999713897705},{"id":"https://openalex.org/keywords/valsartan","display_name":"valsartan","score":0.8700000047683716},{"id":"https://openalex.org/keywords/ace-inhibitors","display_name":"ACE inhibitors","score":0.8460000157356262},{"id":"https://openalex.org/keywords/myocardial-infarction","display_name":"myocardial infarction","score":0.902999997138977},{"id":"https://openalex.org/keywords/renin-angiotensin-aldosterone-system-inhibition","display_name":"renin-angiotensin-aldosterone system inhibition","score":0.8650000095367432},{"id":"https://openalex.org/keywords/survival","display_name":"survival","score":0.597000002861023},{"id":"https://openalex.org/keywords/valiant-trial","display_name":"VALIANT trial","score":0.9200000166893005},{"id":"https://openalex.org/keywords/angiotensin-ii-type-1-receptor","display_name":"angiotensin II type 1 receptor","score":0.7149999737739563},{"id":"https://openalex.org/keywords/high-risk-patients","display_name":"high-risk patients","score":0.5360000133514404},{"id":"https://openalex.org/keywords/drug-comparison","display_name":"drug comparison","score":0.40700000524520874}],"concepts":[{"id":"https://openalex.org/C2778468042","wikidata":"https://www.wikidata.org/wiki/Q273976","display_name":"Blockade","level":3,"score":0.7949123382568359},{"id":"https://openalex.org/C500558357","wikidata":"https://www.wikidata.org/wiki/Q12152","display_name":"Myocardial infarction","level":2,"score":0.7309100031852722},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4787446856498718},{"id":"https://openalex.org/C164705383","wikidata":"https://www.wikidata.org/wiki/Q10379","display_name":"Cardiology","level":1,"score":0.45575517416000366},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.44709840416908264},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.44599416851997375},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4421314299106598},{"id":"https://openalex.org/C2908929049","wikidata":"https://www.wikidata.org/wiki/Q65963433","display_name":"Angiotensin II","level":3,"score":0.44172191619873047}],"mesh":[{"descriptor_ui":"D000068756","descriptor_name":"Valsartan","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009203","descriptor_name":"Myocardial Infarction","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009203","descriptor_name":"Myocardial Infarction","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":true},{"descriptor_ui":"D012084","descriptor_name":"Renin-Angiotensin System","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D013534","descriptor_name":"Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013777","descriptor_name":"Tetrazoles","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014633","descriptor_name":"Valine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047228","descriptor_name":"Angiotensin II Type 1 Receptor Blockers","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":5,"locations":[{"id":"doi:10.3317/jraas.2000.056","doi":"https://doi.org/10.3317/jraas.2000.056","is_oa":false,"landing_page_url":"https://doi.org/10.3317/jraas.2000.056","pdf_url":null,"source":{"id":"https://openalex.org/S107472416","display_name":"Journal of the Renin-Angiotensin-Aldosterone System","issn_l":"1470-3203","issn":["1470-3203","1752-8976"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","norway-1","poland-40","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the Renin-Angiotensin-Aldosterone System","raw_type":"journal-article"},{"id":"pmid:17199221","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17199221","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the renin-angiotensin-aldosterone system : JRAAS","raw_type":"Journal Article"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.564.4117","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.564.4117","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://jra.sagepub.com/content/1/2_suppl/S41.full.pdf","raw_type":"text"},{"id":"pmh:oai:doaj.org/article:9cd075cf08ba45eaa9ecc606d5c87404","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/9cd075cf08ba45eaa9ecc606d5c87404","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Journal of the Renin-Angiotensin-Aldosterone System, Vol 1, Iss 2_suppl, Pp S41-S43 (2000)","raw_type":"article"},{"id":"pmh:oai:doaj.org/article:ac4adcf609fa4bfbb6f88ffd3a2a3932","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/ac4adcf609fa4bfbb6f88ffd3a2a3932","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Journal of the Renin-Angiotensin-Aldosterone System, Vol 1 (2000)","raw_type":"article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":10,"referenced_works":["https://openalex.org/W180946569","https://openalex.org/W1980000060","https://openalex.org/W2021671593","https://openalex.org/W2028455468","https://openalex.org/W2052618446","https://openalex.org/W2055123579","https://openalex.org/W2100767767","https://openalex.org/W2168651123","https://openalex.org/W2312388685","https://openalex.org/W2319658883"],"related_works":["https://openalex.org/W2065037883","https://openalex.org/W4232990541","https://openalex.org/W2038489547","https://openalex.org/W2006804854","https://openalex.org/W2316994246","https://openalex.org/W2144401083","https://openalex.org/W2060507537","https://openalex.org/W2055298851","https://openalex.org/W2168651123","https://openalex.org/W2056362163"],"abstract_inverted_index":{"Angiotensin-converting":[0],"enzyme":[1],"(ACE)":[2],"inhibitors":[3,23],"have":[4,24],"a":[5,59,93,129,135],"well-established":[6],"role":[7],"in":[8,29,42,104,126,134,157,167],"the":[9,43,68,74,83,117,154,158],"management":[10],"of":[11,50,70,96,160],"patients":[12],"with":[13,34,82,98,128,141],"hypertension,":[14],"diabetes,":[15],"heart":[16],"failure":[17],"and":[18,31,36,115],"myocardial":[19],"infarction":[20],"(MI).":[21],"ACE":[22,85,100,131],"been":[25],"particularly":[26,41],"well":[27,60,124],"studied":[28],"acute":[30],"chronic":[32],"MI":[33,138,170],"consistent":[35],"substantial":[37],"survival":[38],"benefits":[39],"demonstrated,":[40],"higher":[44],"risk":[45,137,169],"groups.":[46],"The":[47,102],"recent":[48],"development":[49,159],"angiotensin":[51],"II":[52,72],"(Ang":[53],"II)":[54],"receptor":[55],"blockers":[56],"(ARBs)":[57],"as":[58,123,125],"tolerated":[61],"pharmacological":[62,155],"therapy":[63],"to":[64,113,151],"more":[65],"completely":[66],"inhibit":[67],"actions":[69],"Ang":[71],"at":[73],"AT1-receptor":[75],"level":[76],"raises":[77],"questions":[78],"concerning":[79],"comparative":[80],"efficacy":[81],"proven":[84,130],"inhibitor":[86,132],"experience.":[87],"Two":[88],"major":[89],"trials":[90],"will":[91],"provide":[92],"direct":[94],"comparison":[95],"ARBs":[97,161],"an":[99],"inhibitor.":[101],"Valsartan":[103],"Acute":[105],"Myocardial":[106],"Infarction":[107],"(VALIANT)":[108],"trial":[109],"is":[110,148],"specifically":[111],"designed":[112],"compare":[114],"contrast":[116],"ARB,":[118],"valsartan,":[119],"used":[120],"both":[121],"alone":[122],"combination":[127],"regimen,":[133],"high":[136,168],"population.":[139],"VALIANT,":[140],"its":[142],"three":[143],"arms":[144],"targetting":[145],"14,500":[146],"patients,":[147],"uniquely":[149],"poised":[150],"determine":[152],"whether":[153],"advance":[156],"confers":[162],"additional":[163],"clinical":[164],"(survival)":[165],"value":[166],"patients.":[171]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}